Wave Life Sciences (WVE) Capital Leases (2015 - 2016)
Wave Life Sciences' (WVE) quarterly Capital Leases came in at $16000.0 in Q4 2016, down 79.49% YoY from $78000.0 in Q1 2016, and down 48.39% on a QoQ basis from $31000.0 in Q3 2016.
Powered by 
Analysis
Wave Life Sciences (WVE) Capital Leases (2015 - 2016) Analysis & Trends
Wave Life Sciences (WVE) has 2 years of Capital Leases data on file, last reported at $16000.0 in Q4 2016.
- Quarterly Capital Leases fell 79.49% year-over-year to $16000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $16000.0 (down 79.49% YoY) and the FY2016 annual result came in at $16000.0, down 79.49% from the prior year.
- Capital Leases retreated to $16000.0 in Q4 2016, from $31000.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $94000.0 in Q3 2015 to a low of $16000.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 16,000.00 |
| Sep 30, 2016 | 31,000.00 |
| Jun 30, 2016 | 47,000.00 |
| Mar 31, 2016 | 62,000.00 |
| Dec 31, 2015 | 78,000.00 |
| Sep 30, 2015 | 94,000.00 |